Project will strengthen domestic production of antibody and
other protein-based therapies
MISSISSAUGA, ON, Aug. 7, 2024
/CNW/ - The Government of Canada
continues to strive for innovative solutions and prioritize the
revitalization of long-term domestic biomanufacturing capacity,
positioning Canada at the
forefront of antibody therapeutic development.
Today, Charles Sousa,
Parliamentary Secretary to the Minister of Public Services and
Procurement, on behalf of the Honourable François-Philippe Champagne, Minister of Innovation,
Science and Industry, announced a contribution of $22.4 million through the Strategic Innovation
Fund (SIF) to support a $64.1
million project by Eurofins CDMO Alphora Inc.
This investment will support the construction of a new biologics
facility, increasing domestic production capacity for antibodies
and protein-based therapeutics that will allow Canadians to better
respond to future pandemics. The facility will also enable Eurofins
CDMO Alphora Inc. to accelerate clinical testing and the speed at
which novel therapeutics are brought to market.
With this contribution, Eurofins CDMO Alphora Inc. will
create 120 jobs and 65 co-op positions as well as have the ability
to produce materials for clinical trials and meet commercial
requirements for a production capacity of up to 24.9 million
vials annually.
Quotes
"Rebuilding a robust life sciences sector remains at the
forefront of Canadian economic development. Today's investment in
Eurofins CDMO Alphora Inc. is yet another example of our
government's commitment to secure and strengthen our domestic
biomanufacturing and life sciences sector, providing additional
safeguards against future pandemics while helping create good jobs
for Canadians."
– The Honourable François-Philippe
Champagne, Minister of Innovation, Science and
Industry
"This projects reaffirms Canada's commitment to life sciences and
innovation, while growing the local economy. Today we mark an
important milestone with the announcement of Eurofins' new
Mississauga facility, which will
increase Canada's domestic
production of life–saving therapeutics for all Canadians."
– Charles Sousa, Parliamentary
Secretary to the Minister of Public Services and Procurement
Quick facts
- Canada's Biomanufacturing and
Life Sciences Strategy presents a long–term vision to protect
Canadians against future pandemics and other health emergencies and
to grow an innovative, competitive domestic life sciences
sector.
- Eurofins CDMO Alphora Inc., part of the global network of
Eurofins laboratories, is a contract development manufacturing
organization located in Mississauga,
Ontario. The Ontario
facility specializes in biopharmaceutical research and development
related to clinical and commercial applications of monoclonal
antibody and other protein-based biologic therapeutics.
- In October 2023, Eurofins CDMO
Alphora Inc. received a $2.5 million
grant from the Government of Ontario through the Ontario Together Fund,
which supports the province's pandemic readiness and health care
resiliency.
- Budget 2021 provided a total of $2.2
billion over seven years toward growing a vibrant domestic
life sciences sector and securing pandemic preparedness. This
budget funding provides foundational investments to help build
Canada's talent pipeline and
research systems, as well as to foster the growth of Canadian life
sciences firms.
Associated links
- Biomanufacturing: Advancing life sciences industry in
Canada
- Strategic Innovation Fund
Stay connected
Find more services and information on the Innovation,
Science and Economic Development Canada website.
Follow Innovation, Science and Economic Development Canada on
social media.
X (Twitter): @ISED_CA | Facebook: Canadian
Innovation | Instagram: @cdninnovation |
LinkedIn: Innovation, Science and Economic Development
Canada
SOURCE Innovation, Science and Economic Development Canada